Prophylactic antibiotics in patients undergoing laser resurfacing of the skin. 1999

W Manuskiatti, and R E Fitzpatrick, and M P Goldman, and N Krejci-Papa
Dermatology Associates and Cosmetic Laser Associates of San Diego County, Inc., Encinitas, California 92024, USA.

BACKGROUND Carbon dioxide (CO2) laser resurfacing produces a superficial second-degree burn that needs to be protected from bacterial and fungal infections. OBJECTIVE We investigated the effects of various systemic and topical antimicrobial regimens. METHODS Four different regimens using oral ciprofloxacin, topical antibiotics (intranasal mupirocin ointment and otic solution), oral ketoconazole, and oral fluconazole were tested in four time periods. The frequency and types of the infections with various regimens was compared. RESULTS The study included 356 sequential patients who underwent facial CO2 laser resurfacing. Infections occurred in 27 patients (7.6%). Without antibiotic prophylaxis, 8.2% of patients had bacterial infections from days 3 to 12 after the procedure (average, day 5). With prophylactic ciprofloxacin only, 4.3% of patients had bacterial infections; these occurred almost exclusively after ciprofloxacin was discontinued. For 7 months, patients were randomly assigned to either receive or not receive mupirocin intranasally. All Staphylococcus aureus infections that occurred were seen in patients who had used intranasal mupirocin. Yeast infections were seen in 6 patients (1.7%), but mostly occurred more than 10 days after the procedure. Yeast infections were of approximately equal occurrence in the ciprofloxacin group (2.2%) and in the non-ciprofloxacin group (1.8%). No yeast infections occurred in patients who had undergone antifungal prophylaxis. CONCLUSIONS Post-CO2 resurfacing infections are not rare but can appear subtly and might only be noticeable in the second postoperative week. Prophylactic intranasal mupirocin is ineffective, but ciprofloxacin is effective in preventing infection with both gram-positive and gram-negative bacteria. Oral ketoconazole and fluconazole are effective in preventing yeast infections.

UI MeSH Term Description Entries
D008297 Male Males
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005148 Facial Dermatoses Skin diseases involving the FACE. Favre-Racouchot Syndrome,Nodular Elastoidosis,Facial Dermatosis,Nodular Elastosis,Dermatoses, Facial,Dermatosis, Facial,Elastoidoses, Nodular,Elastoidosis, Nodular,Elastoses, Nodular,Elastosis, Nodular,Favre Racouchot Syndrome,Nodular Elastoidoses,Nodular Elastoses,Syndrome, Favre-Racouchot
D005260 Female Females
D006561 Herpes Simplex A group of acute infections caused by herpes simplex virus type 1 or type 2 that is characterized by the development of one or more small fluid-filled vesicles with a raised erythematous base on the skin or mucous membrane. It occurs as a primary infection or recurs due to a reactivation of a latent infection. (Dorland, 27th ed.) Herpes Simplex Virus Infection
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D013530 Surgical Wound Infection Infection occurring at the site of a surgical incision. Postoperative Wound Infection,Infection, Postoperative Wound,Infection, Surgical Wound,Surgical Site Infection,Wound Infection, Postoperative,Wound Infection, Surgical,Infection, Surgical Site,Infections, Postoperative Wound,Infections, Surgical Site,Infections, Surgical Wound,Postoperative Wound Infections,Surgical Site Infections,Surgical Wound Infections,Wound Infections, Postoperative,Wound Infections, Surgical
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

W Manuskiatti, and R E Fitzpatrick, and M P Goldman, and N Krejci-Papa
August 1996, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.],
W Manuskiatti, and R E Fitzpatrick, and M P Goldman, and N Krejci-Papa
November 1999, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.],
W Manuskiatti, and R E Fitzpatrick, and M P Goldman, and N Krejci-Papa
April 1996, Archives of dermatology,
W Manuskiatti, and R E Fitzpatrick, and M P Goldman, and N Krejci-Papa
February 2002, Otolaryngologic clinics of North America,
W Manuskiatti, and R E Fitzpatrick, and M P Goldman, and N Krejci-Papa
August 2001, Facial plastic surgery clinics of North America,
W Manuskiatti, and R E Fitzpatrick, and M P Goldman, and N Krejci-Papa
September 1996, Seminars in cutaneous medicine and surgery,
W Manuskiatti, and R E Fitzpatrick, and M P Goldman, and N Krejci-Papa
April 1996, Annals of plastic surgery,
W Manuskiatti, and R E Fitzpatrick, and M P Goldman, and N Krejci-Papa
January 2000, Lasers in surgery and medicine,
W Manuskiatti, and R E Fitzpatrick, and M P Goldman, and N Krejci-Papa
November 2012, Journal of drugs in dermatology : JDD,
W Manuskiatti, and R E Fitzpatrick, and M P Goldman, and N Krejci-Papa
August 2004, Facial plastic surgery clinics of North America,
Copied contents to your clipboard!